{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:35:53Z","timestamp":1793136953128,"version":"4.5.0"},"reference-count":4,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jaad.2026.06.122","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:32:58Z","timestamp":1782948778000},"page":"e457-e458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to Huang et al, \u201cReal-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the CRDC\u201d"],"prefix":"10.1016","volume":"95","author":[{"given":"Baocheng","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2026.06.122_bib1","article-title":"Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: an analysis of national multicenter data from the CRDC","author":"Huang","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.122_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7897263","article-title":"Selective immunomodulation of inflammatory pathways in keratinocytes by the Janus Kinase (JAK) inhibitor tofacitinib: implications for the employment of JAK-targeting drugs in psoriasis","volume":"2018","author":"Morelli","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jaad.2026.06.122_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103276","article-title":"JAK inhibitors and autoimmune rheumatic diseases","volume":"22","author":"Benucci","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2026.06.122_bib4","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2025-0180","article-title":"Target trial emulation: bridging observational studies and randomized trials for health decision-making","volume":"15","author":"Riggi","year":"2026","journal-title":"J Comp Eff Res"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226030197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226030197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:29:12Z","timestamp":1793136552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226030197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0190962226030197"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.06.122","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to Huang et al, \u201cReal-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the CRDC\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.06.122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.06.121","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}